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BAckground: Multiple sclerosis (MS) is a chronic and debilitating disease of the 
central nervous system that affects approximately 570,000 persons in the United 
States and 2.3 million worldwide. As most individuals experience initial symptoms 
between the ages of 20 and 40 years, MS can have a significant impact on health-
care consumption, productivity and employment. oBjectives: To compare the 
work productivity impairment in patients initiated on delayed-release dimethyl 
fumarate (DMF; also known as gastro-resistant DMF) and prior approved interferon 
β -1a/b or glatiramer acetate (ABCRE) therapies. Methods: Data were identified 
from the Adelphi MS Disease Specific Programme, a cross-sectional study of MS 
patients in five EU countries and US. Relapsing Remitting MS (RRMS) patients were 
identified, receiving DMF or ABCRE therapies with treatment duration greater than 
12 months. Inverse-probability-weighted regression-adjustment estimated aver-
age treatment effects (ATEs) across DMF and ABCRE cohorts, utilizing a propensity 
score generated from age, gender, EDSS score at current treatment initiation, BMI, 
duration of current treatment, line of therapy, time since MS diagnosis, and num-
ber of comorbid conditions. Work productivity and daily activity impairment due 
to MS, as measured by the Work Productivity and Activity Impairment (WPAI:MS) 
questionnaire, were compared across treatment arms. results: Work productivity 
and activity impairment data was available for 160 and 243 patients, respectively. 
Overall work impairment due to MS was significantly lower in the DMF cohort 
(ATE= -13.92%, p< 0.001, vs. 20.92%). Similarly, impairment while working (presentee-
ism) due to MS was significantly lower in the DMF cohort (ATE= -12.97%, p< 0.001, vs. 
19.45%). No percent of work missed (absenteeism) was observed in the DMF cohort 
(ATE= -2.06%, p= 0.012, vs. 2.06%). Daily activity impairment was significantly lower 
in the DMF cohort (ATE= -17.26%, p< 0.001, vs. 25.31%). conclusions: Compared 
with ABCRE patients, patients on DMF had a significantly lower work productivity 
loss as measured by WPAI-MS.
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oBjectives: MS is a chronic disease associated with substantial clinical and socio-
economic burden. MS patients experience increasing levels of disability as their 
disease progresses. This study investigates the association between increasing MS 
severity and its impact on relapsing-remitting (RRMS) and secondary progressive 
(SPMS) MS patients. Methods: Data were drawn from the Adelphi MS Disease 
Specific Programme, a global (France, Germany, Italy, Spain, UK, USA) cross-sectional 
study with 2965 RRMS and 494 SPMS patients. Multiple logistic, linear and partial 
proportional odds regressions determined the association between physician-
reported MS severity (‘very mild’ [RRMS only], ‘mild’, ‘moderate’, ‘severe’) and pres-
ence of an informal caregiver, weekly informal caregiver hours, and employment 
status, respectively. Regressions adjusted for age, gender, BMI and number of con-
comitant conditions. Reference category was ‘very mild’ and ‘mild’ for RRMS and 
SPMS, respectively. results: For RRMS patients, the likelihood of part-time employ-
ment or unemployment, increased with MS severity (mild: OR = 1.51; moderate: OR = 
3.28; severe: OR = 17.39; p< 0.001 for all) and (mild: OR = 1.18, p= 0.143; moderate: OR = 
2.45, p< 0.001; severe: OR = 8.53, p< 0.001), respectively. Similar results were observed 
in SPMS patients (moderate: OR = 3.41, p= 0.002; severe: OR = 16.85, p< 0.001) and 
(moderate: OR = 3.41, p= 0.002; severe: OR = 16.85, p< 0.001). Increasing level of sever-
ity was associated with a higher likelihood of informal care (RRMS: mild: OR = 1.60, 
p= 0.040; moderate: OR = 4.27, p< 0.001; severe: OR = 15.31, p< 0.001; SPMS: moderate: 
OR = 6.70, p< 0.001; severe: OR = 14.93, p< 0.001) and higher weekly informal car-
egiver hours (RRMS: mild: +0.97, p= 0.014; moderate: +4.52, p< 0.001; severe: +13.27, 
p< 0.001; SPMS: moderate: +8.45, p= 0.006; severe: +18.81, p< 0.001). conclusions: 
Increased MS severity is associated with significantly lower employment as well 
as increased caregiver burden. MS patients should start effective treatments early 
to delay disease progression.
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oBjectives: To compare resource utilization drivers of societal costs for 
Alzheimer’s disease (AD) over 18-months in three countries participating in 
an observational study. Methods: GERAS is a prospective, multi-centre, non-
interventional cohort study in France (n= 419), Germany (n= 550) and the UK 
(n= 526). Resource use of AD patients and caregivers (including informal car-
egiving time and institutionalization), contributing to > 1% total societal costs 
(comprising patient health and social care costs and informal caregiver costs 
- based on 2010 prices) were identified and assessed for country differences 
using Generalised Linear Models of repeated measures or Cox models, adjust-
ing for key patient and caregiver characteristics. results: 18-month societal 
costs per patient: France € 33,300, Germany € 38,200 and UK € 37,900. Caregiver 
time spent assisting patient with basic and instrumental activities of daily liv-
ing (ADL) made the largest contribution to total societal costs in each coun-
try (55-69%). Caregivers in France spent less time on basic and instrumental 
ADLs and were less likely to miss work. Patients in France used more commu-
nity care services and were more likely to spend time in respite care, whereas 
German patients were less likely to use respite care and had slower time to 
institutionalization (Hazard Ratio 0.59 (95% CI 0.41-0.84) Germany, 0.84 (0.60-1.18) 
France, reference UK; p-value 0.0143). UK caregivers spent more time on instru-
mental ADLs while patients used fewer outpatient resources but were more likely 
to receive financial support. No country differences in hospital stays or use of 
AD medication were seen. conclusions: Caregiver time was consistently the 
outcomes and costs was not conducted because the time horizon of the analysis 
did not exceed 1 year. Bivariate sensitivity analysis (SA) was performed. results: 
The cost of the 1st year therapy of compared drugs was: 28,822, 20,810, 57,449 
and 54,332 rubles for piribedil CR, pramipexole ER, ropinirole ER and rasagiline 
respectively. Total therapy cost was estimated by summarizing the cost of therapy 
and ADR costs. Total costs for comparator drugs constituted: 28,930, 21,009, 57,576 
and 54,381 rubles for piribedil CR, pramipexole ER, ropinirole ER and rasagiline 
respectively. Utility effect of the comparison drugs was: -6.1, -8.2, -0.3, -2.7 for 
piribedil CR, pramipexole ER, ropinirole ER and rasagiline respectively. In the 
analysis was found that pramipexole ER has the lowest cost-utility ratio (CUR) 
– 2,562 rubles for 1 point reduction of daytime activity disruption and severity 
of motor impairment as indicated by UPDRS scale. conclusions: Pramipexole 
ER has the lowest CUR. SA confirmed these results. Pramipexole ER was the 
dominant strategy for PD treatment demonstrating higher utility rate at lower 
costs.
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oBjectives: Incobotulinumtoxin-A is a formulation of botulinum neurotoxin type 
A (BoNT/A) that is free of complexing proteins. The advantages of incobotulinum-
toxin-A include flexible treatment intervals determined by clinical need. The objec-
tive of this study was to assess the cost-effectiveness of incobotulinumtoxin-A 
administered with flexible treatment intervals compared to onabotulinumtoxin-A 
in blepharospasm (BLEPH) and cervical dystonia (CD) from the Australian health-
care providers’ perspective. Methods: A Markov state transition model was 
developed to perform a cost-utility analysis (CUA) comparing the cost and health 
benefits of incobotulinumtoxin-A with onabotulinumtoxin-A. The CUA compared 
incobotulinumtoxin-A treatment, given at minimum intervals of 6 weeks and maxi-
mum intervals of 20 weeks, with onabotulinumtoxin-A treatment given at fixed 12 
week intervals. The Markov model consisted of three health states and followed 
patients in weekly cycles for one year. Only direct healthcare costs associated with 
the acquisition and administration of BoNT/A’s were included. Utility values were 
derived from a prospective, open-labelled cohort study. The primary outcome meas-
ure was the incremental cost per quality-adjusted life year (QALY). Univariate and 
probabilistic sensitivity analyses were conducted. results: Incobotulinumtoxin-A 
dominated onabotulinumtoxin-A in both BLEPH and CD. The option to administer 
incobotulinumtoxin-A according to patient needs resulted in patients experienc-
ing fewer number of weeks with symptoms compared to onabotulinumtoxin-A 
administered at fixed 12 week intervals. Incobotulinumtoxin-A provided cost 
savings to the Australian healthcare system. Results held under sensitivity analy-
ses. conclusions: Incobotulinumtoxin-A administered at flexible treatment 
intervals, determined by patient needs, represents a more cost-effective treatment 
option when compared with onabotulinumtoxin-A in the Australian healthcare 
system.
PND61
cosT-uTIlITy of fINgolImoD comPareD WITh DImeThyl fumaraTe (Dmf) 
IN hIghly acTIve relaPsINg remITTINg mulTIPle sclerosIs (rrms) IN 
eNglaND: comParIsoN of a markov aND DIscreTe eveNT sImulaTIoN 
moDel
Kusel J1, Maruszczak M1, Adlard N2
1Costello Medical Consulting Ltd, Cambridge, UK, 2Novartis Pharmaceuticals UK Ltd,  
Camberley, UK
oBjectives: A cohort Markov model based on disability scores was originally 
constructed. Due to constraints of a Markov structure and to test structural uncer-
tainty, a discrete event simulation (DES), based on time to event, was subsequently 
developed. Methods: The same inputs were used in both models, except that 
in the DES a cohort of individual patients that reflected the patients from the 
main fingolimod trials was used and risks of some events were linked to baseline 
characteristics. For both models, published post hoc clinical data in the HA RRMS 
subgroup were taken from the pivotal trials for fingolimod and DMF vs placebo. 
Utility data for each health state and for relapses were used in line with previous 
similar models. Published costs were inflated to NHS cost year 2013–14 and UK 
list prices used for both drugs. Possible Patient Access Scheme (PAS) discount sce-
narios were investigated. results: In the base case, using list prices, the average 
probabilistic incremental cost-effectiveness ratio (ICER) for fingolimod vs DMF 
was found to be £14,076 per QALY using the Markov model (incremental cost: 
£10,358, QALYs: 0.74) and £11,449 per QALY using the DES (incremental cost: £8,694, 
QALYs: 0.76), with a 73% and 72% chance of fingolimod being cost-effective at a 
willingness-to-pay threshold of £30,000/QALY, respectively. Both models were most 
sensitive to treatment effect on disability progression, but robust to other changes 
including incorporation of a wide range of PAS estimates. conclusions: The 
Markov and DES models produced similar results, both concluding that fingolimod 
remains cost-effective in HA RRMS following the introduction of DMF to the UK 
market. This validates the use of a DES in this situation. DES has greater potential 
than the Markov model to be easily adapted in the future to deal with changing 
assumptions on long-term efficacy, treatment sequences and chronic adverse 
events.
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